This recognition highlights CHOP's long-standing commitment to providing world-class care and advancing clinical research for individuals living with Duchenne and Becker muscular dystrophy. The ...
The first gene therapy for children with Duchenne muscular dystrophy has been approved by the U.S. Food and Drug Administration. The therapy can be used in 4- and 5-year-olds with the degenerative ...
Newswise — (COLUMBUS, Ohio) – Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its accelerated approval of ...
A Canadian multicenter study of 115 children shows that new CHEST guideline criteria and REM-sleep-specific measures detect ...
Limb-Girdle Muscular Dystrophy (LGMD) affects an estimated 17,000 Americans and 580,000 people worldwide.
The Food and Drug Administration (FDA) has approved the first gene therapy for the treatment of Duchenne muscular dystrophy (DMD) in children from age 4 through 5 years of age. Pediatric patients who ...
Some children in Northern Ireland who live with a severe form of muscular dystrophy will be able to access new medication on the health service, BBC News understands. The move from the Belfast Health ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved an abbreviated new drug application for a generic version ...
Gene therapies have extended survival in muscular dystrophy, requiring improved care transitions from pediatric to adult systems. Current systems lack adequate staffing, specialists, and communication ...
A cumulative meta-analysis of more than 13,000 patients shows median survival in Duchenne muscular dystrophy has risen from ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results